HDAC8 Inhibitors
Santa Cruz Biotechnology now offers a broad range of HDAC8 Inhibitors. Histone deacetylase proteins (HDACs) are a class of enzymes that remove acetyl groups (O=C-CH3) from an <ε>-N-acetyl lysine amino acid on a histone, allowing histones to wrap DNA more tightly. The deacetylation of histones is associated with transcriptional silencing. Histone deacetylase inhibitors (HDIs) have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptic. HDIs are studied as a treatment for neurodegenerative diseases and have a potential for cancer therapy. HDAC8 Inhibitors offered by Santa Cruz inhibit HDAC8 and, in some cases, other chromatin remodeling and transcription regulation related proteins. View detailed HDAC8 Inhibitor specifications, including HDAC8 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Scriptaid | 287383-59-9 | sc-202807 sc-202807A | 1 mg 5 mg | $64.00 $183.00 | 11 | |
Scriptaid is a hydroxamic acid-based HDAC inhibitor that targets HDAC8 among other HDAC isoforms. It affects histone acetylation patterns, leading to changes in gene expression and potentially influencing cellular processes. | ||||||
1-Naphthohydroxamic Acid | 6953-61-3 | sc-364388 sc-364388A | 5 mg 25 mg | $87.00 $337.00 | ||
1-Naphthohydroxamic acid is a hydroxamate-based compound that inhibits HDAC8. By interfering with HDAC8's deacetylation activity, it modulates histone acetylation and gene expression, potentially impacting various cellular functions. | ||||||
Droxinostat | 99873-43-5 | sc-364485 sc-364485A | 5 mg 25 mg | $85.00 $454.00 | 1 | |
Droxinostat is a hydroxamate-based HDAC inhibitor with selectivity for HDAC8. It modulates histone acetylation patterns, influencing gene expression and potentially impacting cellular processes related to epigenetic regulation. | ||||||
Pimelic Diphenylamide 106 | 937039-45-7 | sc-364589 sc-364589A | 1 mg 5 mg | $41.00 $74.00 | ||
Pimelic diphenylamide 106 is a compound that targets class I HDACs, including HDAC8. It influences histone acetylation levels, potentially affecting gene expression and cellular processes associated with epigenetic regulation. | ||||||
PCI-34051 | 950762-95-5 | sc-364566 sc-364566A | 10 mg 100 mg | $189.00 $1671.00 | 5 | |
Hydroxamate-based inhibitor that specifically targets HDAC8, promoting hyperacetylation of histones and proteins, affecting gene expression. | ||||||
PCI-24781 | 783355-60-2 | sc-364565 sc-364565A | 5 mg 50 mg | $186.00 $1357.00 | 1 | |
PCI-24781 is a hydroxamic acid-based HDAC inhibitor that includes HDAC8 among its targets. By altering histone acetylation, it can affect gene expression dynamics and potentially play a role in regulating cellular functions. | ||||||
TC-H 106 | 937039-45-7 | sc-362801 sc-362801A | 10 mg 50 mg | $155.00 $620.00 | ||
TC-H 106 is an HDAC inhibitor that selectively targets HDAC8. Its mechanism of action involves modulating histone acetylation patterns, potentially impacting gene expression dynamics and cellular processes. Please be aware that scientific understanding can change over time, and there may have been developments or refinements in our knowledge since September 2021. Always refer to more recent sources for the latest information. | ||||||